文献速递颈动脉与弓上血管

血管质量倡议中颈动脉疾病患者选择与治疗的地区差异

Regional variation in patient selection and treatment for carotid artery disease in the Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2017-03-27

基于VQI 2009-2015年57,555例颈动脉血运重建(CEA 49,179例,CAS 8,376例)的注册数据,分析地区间患者选择、手术技术和围术期管理的差异。结果显示无症状患者比例、<70%狭窄干预率、高龄干预率、术前用药及CEA技术(转流、鱼精蛋白、补片)和CAS保护装置使用均存在显著地区差异。

要点

  • CEA无症状患者比例中位56%(范围46%-69%),CAS为36%(29%-51%),地区差异显著。
  • 无症状<70%狭窄干预率CEA 3%-9%,CAS 3%-22%;>80岁干预率CEA 12%-27%,CAS 8%-26%。
  • CEA中转流、鱼精蛋白和补片使用率及CAS无保护装置率均呈现显著地区差异。

核心结论

  • 尽管有临床基准指导颈动脉疾病管理,临床实践仍存在广泛地区差异,包括无症状患者CAS治疗比例和术前药物管理。

研究设计与样本

  • 回顾性队列研究,使用Vascular Quality Initiative(VQI)注册数据,纳入2009-2015年所有CEA或CAS患者,共57,555例手术(CEA 49,179例,CAS 8,376例),按去标识化地区分组比较。

主要发现

  • CEA无症状患者比例中位56%(范围46%-69%,P<.01),CAS为36%(范围29%-51%,P<.01)。
  • 无症状<70%狭窄干预率CEA 3%-9%(P<.01),CAS 3%-22%(P<.01);>80岁无症状干预率CEA 12%-27%(P<.01),CAS 8%-26%(P<.01)。
  • CAS术前CTA或MRA使用率31%-83%(P<.01);术前联合阿司匹林和他汀治疗率CEA 53%-77%(P<.01),CAS 62%-80%(P<.01)。
  • CEA中转流使用率36%-83%(P<.01),鱼精蛋白32%-89%(P<.01),补片87%-99%(P<.01);CAS无保护装置率1%-8%(P<.01)。

临床怎么用

  • 应关注地区间颈动脉血运重建实践差异,针对无症状患者选择、术前药物治疗及手术技术开展质量改进项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous studies involving large administrative data sets have revealed regional variation in the demographics of patients selected for carotid endarterectomy (CEA) and carotid artery stenting (CAS) but lacked clinical granularity. This study aimed to evaluate regional variation in patient selection and operative technique for carotid artery revascularization using a detailed clinical registry. METHODS: All patients who underwent CEA or CAS from 2009 to 2015 were identified in the Vascular Quality Initiative (VQI). Deidentified regional groups were used to evaluate variation in patient selection, operative technique, and perioperative management. χ2 analysis was used to identify significant variation across regions. RESULTS: A total of 57,555 carotid artery revascularization procedures were identified. Of these, 49,179 patients underwent CEA (asymptomatic: median, 56%; range, 46%-69%; P < .01) and 8376 patients underwent CAS (asymptomatic: median, 36%; range, 29%-51%; P < .01). There was significant regional variation in the proportion of asymptomatic patients being treated for carotid stenosis <70% in CEA (3%-9%; P < .01) vs CAS (3%-22%; P < .01). There was also significant variation in the rates of intervention for asymptomatic patients older than 80 years (CEA, 12%-27% [P < .01]; CAS, 8%-26% [P < .01]). Preoperative computed tomography angiography or magnetic resonance angiography in the CAS cohort also varied widely (31%-83%; P < .01), as did preoperative medical management with combined aspirin and statin (CEA, 53%-77% [P < .01]; CAS, 62%-80% [P < .01]). In the CEA group, the use of shunt (36%-83%; P < .01), protamine (32%-89%; P < .01), and patch (87%-99%; P < .01) varied widely. Similarly, there was regional variation in frequency of CAS done without a protection device (1%-8%; P < .01). CONCLUSIONS: Despite clinical benchmarks aimed at guiding management of carotid disease, wide variation in clinical practice exists, including the proportion of asymptomatic patients being treated by CAS and preoperative medical management. Additional intraoperative variables, including the use of a patch and protamine during CEA and use of a protection device during CAS, displayed similar variation in spite of clear guidelines. Quality improvement projects could be directed toward improved adherence to benchmarks in these areas.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shean KE, McCallum JC, Soden PA, et al. Regional variation in patient selection and treatment for carotid artery disease in the Vascular Quality Initiative. J Vasc Surg. 2017. PMID: 28359719. doi:10.1016/j.jvs.2017.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。